Cona, A.; Tavelli, A.; Agrenzano, S.; Hafeez, N.; Scianna, G.; Maria, A.; Marino, F.; Cruz, E.D.L.; Giorgio, M.D.; Osorio, E.;
et al. Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience. Microorganisms 2024, 12, 1436.
https://doi.org/10.3390/microorganisms12071436
AMA Style
Cona A, Tavelli A, Agrenzano S, Hafeez N, Scianna G, Maria A, Marino F, Cruz EDL, Giorgio MD, Osorio E,
et al. Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience. Microorganisms. 2024; 12(7):1436.
https://doi.org/10.3390/microorganisms12071436
Chicago/Turabian Style
Cona, Andrea, Alessandro Tavelli, Stefano Agrenzano, Neha Hafeez, Giovanni Scianna, Angelo Maria, Francesco Marino, Elizabeth De La Cruz, Maria Di Giorgio, Eglys Osorio,
and et al. 2024. "Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience" Microorganisms 12, no. 7: 1436.
https://doi.org/10.3390/microorganisms12071436
APA Style
Cona, A., Tavelli, A., Agrenzano, S., Hafeez, N., Scianna, G., Maria, A., Marino, F., Cruz, E. D. L., Giorgio, M. D., Osorio, E., Cucinella, G., Luca, A., Provenzani, A., Vitulo, P., Bertani, A., Grossi, P. A., & Mularoni, A.
(2024). Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience. Microorganisms, 12(7), 1436.
https://doi.org/10.3390/microorganisms12071436
